nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK8—cartilage tissue—osteoarthritis	0.0144	0.29	CbGeAlD
Nilotinib—CDC42BPB—tendon—osteoarthritis	0.00272	0.0547	CbGeAlD
Nilotinib—MAPK8—tendon—osteoarthritis	0.00246	0.0495	CbGeAlD
Nilotinib—MAP4K1—tendon—osteoarthritis	0.00224	0.045	CbGeAlD
Nilotinib—BRAF—tendon—osteoarthritis	0.00205	0.0411	CbGeAlD
Nilotinib—HCK—tendon—osteoarthritis	0.00187	0.0375	CbGeAlD
Nilotinib—ABL2—tendon—osteoarthritis	0.00186	0.0373	CbGeAlD
Nilotinib—EPHA4—tendon—osteoarthritis	0.0017	0.0341	CbGeAlD
Nilotinib—CA3—tendon—osteoarthritis	0.00168	0.0337	CbGeAlD
Nilotinib—CA9—tendon—osteoarthritis	0.00161	0.0322	CbGeAlD
Nilotinib—MAPK14—tendon—osteoarthritis	0.00156	0.0314	CbGeAlD
Nilotinib—FGR—tendon—osteoarthritis	0.00156	0.0313	CbGeAlD
Nilotinib—CA14—tendon—osteoarthritis	0.00152	0.0306	CbGeAlD
Nilotinib—EPHB4—tendon—osteoarthritis	0.00148	0.0298	CbGeAlD
Nilotinib—EPHA2—tendon—osteoarthritis	0.00146	0.0292	CbGeAlD
Nilotinib—TEK—tendon—osteoarthritis	0.00142	0.0285	CbGeAlD
Nilotinib—EPHB6—tendon—osteoarthritis	0.00136	0.0273	CbGeAlD
Nilotinib—PDGFRA—tendon—osteoarthritis	0.00129	0.0258	CbGeAlD
Nilotinib—MAP2K5—tendon—osteoarthritis	0.00116	0.0233	CbGeAlD
Nilotinib—CSF1R—tendon—osteoarthritis	0.00113	0.0227	CbGeAlD
Nilotinib—PDGFRB—tendon—osteoarthritis	0.001	0.0202	CbGeAlD
Nilotinib—ABL1—tendon—osteoarthritis	0.000895	0.018	CbGeAlD
Nilotinib—CA4—tendon—osteoarthritis	0.000735	0.0148	CbGeAlD
Nilotinib—CA2—tendon—osteoarthritis	0.00061	0.0122	CbGeAlD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—osteoarthritis	0.00011	0.000116	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—IL6—osteoarthritis	0.00011	0.000116	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—IL6—osteoarthritis	0.00011	0.000116	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—IL6—osteoarthritis	0.000109	0.000115	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—FMOD—osteoarthritis	0.000109	0.000115	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—IL6—osteoarthritis	0.000109	0.000115	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGES—osteoarthritis	0.000108	0.000114	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—FMOD—osteoarthritis	0.000108	0.000114	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—IL6—osteoarthritis	0.000108	0.000114	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP3—osteoarthritis	0.000108	0.000113	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—IL6—osteoarthritis	0.000108	0.000113	CbGpPWpGaD
Nilotinib—KIT—Disease—SMAD3—osteoarthritis	0.000105	0.000111	CbGpPWpGaD
Nilotinib—CA12—Metabolism—PTGS2—osteoarthritis	0.000105	0.000111	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IGF1—osteoarthritis	0.000105	0.000111	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TGFB1—osteoarthritis	0.000104	0.000109	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—IL6—osteoarthritis	0.000104	0.000109	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—ESR1—osteoarthritis	0.000103	0.000108	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—SMAD3—osteoarthritis	0.000103	0.000108	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1A—osteoarthritis	0.000102	0.000107	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—BMP2—osteoarthritis	0.0001	0.000105	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—SMAD3—osteoarthritis	9.96e-05	0.000105	CbGpPWpGaD
Nilotinib—KIT—Immune System—CRP—osteoarthritis	9.95e-05	0.000105	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—osteoarthritis	9.95e-05	0.000105	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1A—osteoarthritis	9.94e-05	0.000105	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1A—osteoarthritis	9.9e-05	0.000104	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—BMP2—osteoarthritis	9.81e-05	0.000103	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—SMAD3—osteoarthritis	9.75e-05	0.000103	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—osteoarthritis	9.74e-05	0.000102	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TNF—osteoarthritis	9.71e-05	0.000102	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—IL6—osteoarthritis	9.59e-05	0.000101	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL1B—osteoarthritis	9.54e-05	0.0001	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP9—osteoarthritis	9.5e-05	0.0001	CbGpPWpGaD
Nilotinib—HCK—Disease—PTGS2—osteoarthritis	9.47e-05	9.96e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP9—osteoarthritis	9.46e-05	9.95e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGES—osteoarthritis	9.43e-05	9.92e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1A—osteoarthritis	9.42e-05	9.92e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CRP—osteoarthritis	9.42e-05	9.92e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—IL6—osteoarthritis	9.33e-05	9.82e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—BMP2—osteoarthritis	9.3e-05	9.78e-05	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—IL6—osteoarthritis	9.3e-05	9.78e-05	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—IL6—osteoarthritis	9.24e-05	9.72e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP3—osteoarthritis	9.03e-05	9.5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP9—osteoarthritis	9.01e-05	9.48e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTO1—osteoarthritis	9.01e-05	9.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SMAD3—osteoarthritis	8.97e-05	9.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—SMAD3—osteoarthritis	8.97e-05	9.44e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP3—osteoarthritis	8.94e-05	9.41e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGES—osteoarthritis	8.89e-05	9.35e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGES—osteoarthritis	8.81e-05	9.27e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—LEP—osteoarthritis	8.77e-05	9.23e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—BGN—osteoarthritis	8.72e-05	9.18e-05	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—IL6—osteoarthritis	8.69e-05	9.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—IL6—osteoarthritis	8.66e-05	9.12e-05	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—IL6—osteoarthritis	8.66e-05	9.11e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL1B—osteoarthritis	8.64e-05	9.1e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL1B—osteoarthritis	8.64e-05	9.1e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL1B—osteoarthritis	8.61e-05	9.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CRP—osteoarthritis	8.49e-05	8.93e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—PTGS2—osteoarthritis	8.38e-05	8.82e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ESR1—osteoarthritis	8.37e-05	8.81e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—LEP—osteoarthritis	8.33e-05	8.77e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CRP—osteoarthritis	8.31e-05	8.75e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CRP—osteoarthritis	8.27e-05	8.71e-05	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—IL6—osteoarthritis	8.27e-05	8.7e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FN1—osteoarthritis	8.27e-05	8.7e-05	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—IL6—osteoarthritis	8.23e-05	8.66e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SMAD3—osteoarthritis	8.17e-05	8.6e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1A—osteoarthritis	8.15e-05	8.58e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP3—osteoarthritis	8.14e-05	8.57e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SMAD3—osteoarthritis	8.09e-05	8.52e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BMP2—osteoarthritis	8.04e-05	8.46e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PTGS2—osteoarthritis	8.03e-05	8.45e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ESR1—osteoarthritis	7.96e-05	8.37e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CRP—osteoarthritis	7.88e-05	8.29e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FN1—osteoarthritis	7.86e-05	8.27e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—IL6—osteoarthritis	7.84e-05	8.25e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TGFB1—osteoarthritis	7.83e-05	8.24e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TGFB1—osteoarthritis	7.8e-05	8.2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP3—osteoarthritis	7.71e-05	8.11e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTGS2—osteoarthritis	7.7e-05	8.1e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TGFB1—osteoarthritis	7.68e-05	8.09e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TGFB1—osteoarthritis	7.65e-05	8.05e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTO1—osteoarthritis	7.63e-05	8.03e-05	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL6—osteoarthritis	7.62e-05	8.02e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—IL6—osteoarthritis	7.49e-05	7.88e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TGFB1—osteoarthritis	7.43e-05	7.81e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—BGN—osteoarthritis	7.39e-05	7.77e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SMAD3—osteoarthritis	7.37e-05	7.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—ESR1—osteoarthritis	7.32e-05	7.7e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—osteoarthritis	7.31e-05	7.7e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TGFB1—osteoarthritis	7.28e-05	7.67e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—osteoarthritis	7.28e-05	7.66e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IGF1—osteoarthritis	7.24e-05	7.62e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—SMAD3—osteoarthritis	7.2e-05	7.58e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoarthritis	7.19e-05	7.57e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FMOD—osteoarthritis	7.13e-05	7.5e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—LEP—osteoarthritis	6.98e-05	7.35e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SMAD3—osteoarthritis	6.97e-05	7.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP3—osteoarthritis	6.94e-05	7.31e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—osteoarthritis	6.93e-05	7.3e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—IL6—osteoarthritis	6.92e-05	7.29e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—LEP—osteoarthritis	6.92e-05	7.28e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IGF1—osteoarthritis	6.89e-05	7.25e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1B—osteoarthritis	6.89e-05	7.25e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—TGFB1—osteoarthritis	6.84e-05	7.2e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CRP—osteoarthritis	6.81e-05	7.17e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP3—osteoarthritis	6.8e-05	7.15e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTGS2—osteoarthritis	6.77e-05	7.12e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTGS2—osteoarthritis	6.77e-05	7.12e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoarthritis	6.72e-05	7.07e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ESR1—osteoarthritis	6.67e-05	7.02e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTO1—osteoarthritis	6.64e-05	6.99e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ESR1—osteoarthritis	6.61e-05	6.95e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FN1—osteoarthritis	6.59e-05	6.93e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FN1—osteoarthritis	6.52e-05	6.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP3—osteoarthritis	6.44e-05	6.78e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—BGN—osteoarthritis	6.43e-05	6.77e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TGFB1—osteoarthritis	6.3e-05	6.63e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—LEP—osteoarthritis	6.3e-05	6.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SMAD3—osteoarthritis	6.28e-05	6.61e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTO1—osteoarthritis	6.26e-05	6.59e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—osteoarthritis	6.24e-05	6.57e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1B—osteoarthritis	6.21e-05	6.53e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTO1—osteoarthritis	6.21e-05	6.53e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTGS2—osteoarthritis	6.16e-05	6.49e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SMAD3—osteoarthritis	6.15e-05	6.47e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—BGN—osteoarthritis	6.06e-05	6.38e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ESR1—osteoarthritis	6.01e-05	6.33e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—BGN—osteoarthritis	6.01e-05	6.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—LEP—osteoarthritis	5.96e-05	6.27e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FN1—osteoarthritis	5.94e-05	6.25e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—osteoarthritis	5.91e-05	6.22e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—osteoarthritis	5.9e-05	6.21e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—osteoarthritis	5.88e-05	6.19e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—osteoarthritis	5.87e-05	6.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—osteoarthritis	5.83e-05	6.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SMAD3—osteoarthritis	5.83e-05	6.14e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CXCL8—osteoarthritis	5.83e-05	6.13e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGES—osteoarthritis	5.81e-05	6.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF1—osteoarthritis	5.77e-05	6.07e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF1—osteoarthritis	5.72e-05	6.02e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ESR1—osteoarthritis	5.69e-05	5.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FN1—osteoarthritis	5.62e-05	5.92e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—osteoarthritis	5.6e-05	5.89e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—osteoarthritis	5.59e-05	5.88e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP3—osteoarthritis	5.57e-05	5.86e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CXCL8—osteoarthritis	5.54e-05	5.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—LEP—osteoarthritis	5.37e-05	5.65e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—osteoarthritis	5.32e-05	5.6e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—osteoarthritis	5.3e-05	5.57e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—osteoarthritis	5.27e-05	5.54e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LEP—osteoarthritis	5.26e-05	5.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—osteoarthritis	5.26e-05	5.53e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—osteoarthritis	5.21e-05	5.49e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF1—osteoarthritis	5.2e-05	5.48e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—osteoarthritis	5.19e-05	5.46e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—osteoarthritis	5.18e-05	5.46e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—osteoarthritis	5.16e-05	5.43e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—osteoarthritis	5.16e-05	5.43e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ESR1—osteoarthritis	5.13e-05	5.4e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FN1—osteoarthritis	5.06e-05	5.33e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—osteoarthritis	5.06e-05	5.33e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—osteoarthritis	5.06e-05	5.33e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—osteoarthritis	5.04e-05	5.31e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SMAD3—osteoarthritis	5.04e-05	5.31e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ESR1—osteoarthritis	5.02e-05	5.28e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—osteoarthritis	5.01e-05	5.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LEP—osteoarthritis	4.98e-05	5.25e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FN1—osteoarthritis	4.96e-05	5.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—osteoarthritis	4.94e-05	5.2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF1—osteoarthritis	4.93e-05	5.18e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—osteoarthritis	4.91e-05	5.17e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—osteoarthritis	4.89e-05	5.15e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	4.77e-05	5.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ESR1—osteoarthritis	4.76e-05	5.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FN1—osteoarthritis	4.7e-05	4.95e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL8—osteoarthritis	4.64e-05	4.88e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL8—osteoarthritis	4.6e-05	4.84e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—osteoarthritis	4.46e-05	4.69e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1—osteoarthritis	4.44e-05	4.67e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1—osteoarthritis	4.34e-05	4.57e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—osteoarthritis	4.34e-05	4.57e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LEP—osteoarthritis	4.31e-05	4.54e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—osteoarthritis	4.27e-05	4.5e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—osteoarthritis	4.25e-05	4.47e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—osteoarthritis	4.22e-05	4.44e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—osteoarthritis	4.22e-05	4.44e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—osteoarthritis	4.2e-05	4.42e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL8—osteoarthritis	4.19e-05	4.4e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—osteoarthritis	4.16e-05	4.38e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—osteoarthritis	4.13e-05	4.35e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1—osteoarthritis	4.12e-05	4.33e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ESR1—osteoarthritis	4.11e-05	4.33e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTO1—osteoarthritis	4.09e-05	4.31e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FN1—osteoarthritis	4.06e-05	4.28e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—osteoarthritis	4.03e-05	4.24e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—osteoarthritis	4.03e-05	4.24e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BGN—osteoarthritis	3.96e-05	4.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL8—osteoarthritis	3.96e-05	4.17e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	3.88e-05	4.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—osteoarthritis	3.8e-05	4e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—osteoarthritis	3.79e-05	3.98e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—osteoarthritis	3.69e-05	3.88e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—osteoarthritis	3.64e-05	3.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—osteoarthritis	3.58e-05	3.77e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—osteoarthritis	3.57e-05	3.76e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—osteoarthritis	3.56e-05	3.75e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—osteoarthritis	3.49e-05	3.68e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—osteoarthritis	3.46e-05	3.64e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—osteoarthritis	3.44e-05	3.62e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—osteoarthritis	3.43e-05	3.61e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—osteoarthritis	3.42e-05	3.6e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—osteoarthritis	3.36e-05	3.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—osteoarthritis	3.31e-05	3.49e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—osteoarthritis	3.27e-05	3.44e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—osteoarthritis	3.23e-05	3.4e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—osteoarthritis	3.18e-05	3.34e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—osteoarthritis	3.16e-05	3.33e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—osteoarthritis	3.12e-05	3.28e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—osteoarthritis	3.11e-05	3.27e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—osteoarthritis	3.1e-05	3.26e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—osteoarthritis	3.05e-05	3.21e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—osteoarthritis	3.04e-05	3.2e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—osteoarthritis	3.02e-05	3.18e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—osteoarthritis	3e-05	3.15e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—osteoarthritis	2.95e-05	3.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—osteoarthritis	2.88e-05	3.03e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—osteoarthritis	2.86e-05	3.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—osteoarthritis	2.86e-05	3.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—osteoarthritis	2.66e-05	2.8e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—osteoarthritis	2.61e-05	2.74e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—osteoarthritis	2.6e-05	2.74e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—osteoarthritis	2.59e-05	2.73e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—osteoarthritis	2.58e-05	2.72e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—osteoarthritis	2.51e-05	2.64e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—osteoarthritis	2.49e-05	2.62e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—osteoarthritis	2.47e-05	2.6e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—osteoarthritis	2.35e-05	2.47e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—osteoarthritis	2.3e-05	2.42e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—osteoarthritis	2.23e-05	2.34e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—osteoarthritis	2.14e-05	2.25e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—osteoarthritis	2.12e-05	2.23e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—osteoarthritis	2e-05	2.11e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—osteoarthritis	1.96e-05	2.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—osteoarthritis	1.86e-05	1.96e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—osteoarthritis	1.85e-05	1.95e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—osteoarthritis	1.74e-05	1.83e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—osteoarthritis	1.73e-05	1.82e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—osteoarthritis	1.61e-05	1.69e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—osteoarthritis	1.14e-05	1.2e-05	CbGpPWpGaD
